Table 2.
Variation of anthropometric and metabolic indicators after treatment of obesity MDT.
| n | Baseline | After follow-up | p value∗ | |
|---|---|---|---|---|
| Weight (kg) | 119 | 89.7 ± 20.0 | 80.9 ± 17.1 | <0.001 |
| Lean body mass (kg) | 119 | 51.7 ± 10.9 | 50.5 ± 10.0 | <0.001 |
| Hip circumference (cm) | 119 | 109.9 ± 10.8 | 105.8 ± 9.5 | <0.001 |
| Muscle mass of lower extremities (kg) | 119 | 16.1 ± 3.6 | 15.7 ± 3.4 | <0.001 |
| Body adiposity index | 119 | 33.9 ± 4.9 | 32.0 ± 4.3 | <0.001 |
| Fat-free mass index | 119 | 17.0 ± 6.2 | 15.2 ± 7.2 | 0.043 |
| Fasting plasma glucose (mmol/L) | 119 | 6.0 ± 1.5 | 5.5 ± 0.9 | 0.002 |
| Fasting insulin (μIU/mL) | 119 | 19.0 ± 10.8 | 13.8 ± 6.6 | 0.002 |
| HOMA-IR | 119 | 4.8 ± 2.6 | 3.2 ± 1.5 | <0.001 |
| HOMA-β | 119 | 256.7 ± 39.1 | 202.9 ± 21.4 | 0.134 |
| HbA1c (%) | 34 | 6.89 ± 0.26 | 6.33 ± 0.93 | 0.038 |
| ALT (U/L) | 54 | 36.0 ± 3.3 | 24.7 ± 2.2 | 0.001 |
| AST (U/L) | 53 | 23.8 ± 1.6 | 20.1 ± 1.0 | 0.021 |
| Uric acid (μmol/L) | 53 | 359.0 ± 91.9 | 351.6 ± 74.6 | 0.480 |
| Triglyceride (mmol/L) | 54 | 2.15 ± 0.23 | 2.06 ± 0.37 | 0.745 |
| TCHO (mmol/L) | 54 | 4.70 ± 0.14 | 4.86 ± 0.17 | 0.320 |
| HDL-c (mmol/L) | 54 | 1.06 ± 0.26 | 1.19 ± 0.30 | <0.001 |
| LDL-c (mmol/L) | 54 | 2.86 ± 0.96 | 2.85 ± 0.88 | 0.963 |
ALT: glutamic-pyruvic transaminase; AST: glutamic-oxaloacetic transaminase; TCHO: total cholesterol; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol. ∗χ2 test for categorical variables and Student's t-test for continuous variables.